T helper type 1 cytokine response (Th1 response)

The T helper type 1 (Th1) cytokine response is a physiological process characterized by the production of a specific set of pro-inflammatory cytokines, primarily interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α) [StatPearls, NBK553086]. This response is essential for cell-mediated immunity, serving as the primary defense mechanism against intracellular pathogens such as viruses and certain bacteria, and playing a critical role in anti-tumor surveillance [PubMed, 31102143]. While necessary for host protection, a dysregulated or chronically overactive Th1 response is a major driver of tissue damage in autoimmune diseases, including rheumatoid arthritis, Crohn's disease, and multiple sclerosis [NIH, 2023]. Pharmacological intervention does not target the "response" as a single entity but instead targets individual components of the pathway, such as TNF-α or the IL-12/IL-23 axis, to reduce systemic inflammation [Nature Reviews Rheumatology, 2020]. Conversely, in the context of cancer immunotherapy, various agents aim to stimulate the Th1 response to enhance the effector functions of cytotoxic T cells against malignant cells [Frontiers in Immunology, 2021].

Other names

Type 1 immunityTh1-mediated immune responseCell-mediated immune responseTh1 cytokine profile

Modulation of the Th1 pathway occurs through the neutralization of specific pro-inflammatory cytokines (e.g., TNF-alpha, IL-12), inhibition of intracellular signaling (e.g., JAK-STAT pathway), or broad suppression of T-cell activation.